Evidence map›Paper›PMID 40180676›Full record

ArticleAnnals of intensive care2025

Impact of early versus conventional kidney replacement therapy initiation in tumor lysis syndrome: a target trial emulation.

Justine Serre, Guillaume Mulier, Charlotte Boud'hors, Marie Lemerle, Moustafa Abdel-Nabey, Corentin Orvain, Anis Chaba, Lucie Biard, Julien Demiselle, Lara Zafrani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Justine SerreDepartment of Medical Intensive Care, Hôpital Saint-Louis, AP-HP, Paris, France.
Guillaume MulierDepartment of Biostatistics and Medical Information, AP-HP, Hôpital Saint-Louis, Université Paris Cité, Paris, France.
Charlotte Boud'horsDepartment of Nephrology, Dialysis, Transplantation, CHU Angers, Angers, France.
Marie LemerleDepartment of Medical Intensive Care, CHU Angers, Angers, France.
Moustafa Abdel-NabeyDepartment of Medical Intensive Care, Hôpital Saint-Louis, AP-HP, Paris, France.
Corentin OrvainDepartment of Hematology, CHU Angers, Angers, France.
Anis ChabaDepartment of Medical Intensive Care, Hôpital Saint-Louis, AP-HP, Paris, France.
Lucie BiardDepartment of Biostatistics and Medical Information, AP-HP, Hôpital Saint-Louis, Université Paris Cité, Paris, France.
Julien Demiselle *Department of Medical Intensive Care, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France.
Lara Zafrani *Department of Medical Intensive Care, Hôpital Saint-Louis, AP-HP, Paris, France. lara.zafrani@aphp.fr.ORCID http://orcid.org/0000-0002-7805-3116

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the context of tumor lysis syndrome (TLS), the optimal timing and criteria for initiating kidney replacement therapy (KRT) remain unclear. This study aims to assess the effect of initiating KRT at various phosphatemia thresholds on Major Adverse Kidney Events at day 30 (MAKE30). METHODS AND

resultsWe retrospectively emulated a pragmatic clinical trial comparing the effect of KRT initiation at various phosphatemia thresholds versus a conventional approach during TLS on MAKE30. All consecutive patients admitted to the ICU at Saint-Louis University hospital in Paris and Angers University hospital between January 2007 and June 2020, presenting with laboratory TLS were included. The design criteria of a clinical trial were mimicked by using the cloning, censoring and weighting method. The primary outcome was the MAKE30 composite outcome, considering only KRT requirement between day 7 and day 30 for the dialysis criteria. We evaluated multiple phosphatemia thresholds to guide KRT initiation, ranging from 6.20 mg.dL

conclusionOur results do not support the strategy of KRT initiation based on a sole critical phosphatemia level in TLS patients.

Indexed as

Acute kidney injuryKidney replacement therapyTumor lysis syndrome

Identifiers

PMID40180676
PMCPMC11968619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.